Hem/Onc Roundup: Radiation for Prostate Cancer, Multiple Myeloma Clinical Trials, and More

Shorter, Higher Dose Radiation Regimen is Effective for Advanced Prostate Cancer

Radiation therapy administered in shorter spans at higher doses is an effective and safe option for high-risk prostate cancer, according to a new study from the UCLA Jonsson Comprehensive Cancer Center. Researchers sought to verify whether shortening the standard 45-day radiation regimen to a five-day course at increased dosage is a viable treatment option for men with aggressive prostate cancer.

Shorter, Higher Dose Radiation Regimen is Effective for Advanced Prostate Cancer

Recent Clinical Trials for Newly Diagnosed Multiple Myeloma, with Dr. Raj Chakraborty

DocWire News spoke with Raj Chakraborty, MD, assistant professor of medicine at Columbia University Irving Medical Center, Division of Hematology/Oncology, about promising results from current clinical trials for newly-diagnosed multiple myeloma.

Recent Clinical Trials for Newly Diagnosed Multiple Myeloma, with Dr. Raj Chakraborty

Paper Conversation Aids Are Helpful in Improving Outcomes for Lower Socioeconomic Status Breast Cancer Patients

Using paper conversation aids when speaking with women of lower socioeconomic status (SES) with breast cancer improved outcomes compared to usual care alone, according to a study.

“Conversation aids increase patients’ knowledge and participation in decision making and improve risk perceptions without increasing the visit duration. They can be integrated into routine care and electronic health records,” the study authors explained.

Paper Conversation Aids Are Helpful in Improving Outcomes for Lower Socioeconomic Status Breast Cancer Patients

Does Perioperative Chemotherapy for Pancreatic Cancer Improve Outcomes?

In a randomized phase II trial, researchers assessed whether perioperative chemotherapy improved overall survival (OS) for patients with pancreatic cancer who underwent surgery. This multicenter trial sought to measure two-year OS in patients with pancreatic ductal adenocarcinoma (PDA) who underwent chemotherapy in the 12 weeks prior to and following pancreatic resection.

Does Perioperative Chemotherapy for Pancreatic Cancer Improve Outcomes?